The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System DOI
Jianxing Zhou, Zipeng Wei,

Weipeng Lai

и другие.

British Journal of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 10, 2024

The use of (GLP-1 RAs) among pregnant women is escalating, yet safety data remain insufficient. This study aims to comprehensively assess adverse drug reactions (ADRs) associated with GLP-1 RAs in using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Язык: Английский

Data mining study on adverse events of tirzepatide based on FAERS database DOI

Yan Huo,

Minghua Ma, Xiaolan Liao

и другие.

Expert Opinion on Drug Safety, Год журнала: 2024, Номер unknown, С. 1 - 9

Опубликована: Июль 15, 2024

Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes or obesity. To explore the safety profile of tirzepatide in real-world clinical applications.

Язык: Английский

Процитировано

1
Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System DOI
Jianxing Zhou, Zipeng Wei, Wei Huang

и другие.

Annals of Pharmacotherapy, Год журнала: 2024, Номер unknown

Опубликована: Авг. 20, 2024

Alzheimer's disease (AD) is a neurodegenerative condition leading to memory loss, cognitive impairment, and neuropsychiatric symptoms. Second-generation antipsychotics (SGAs) are commonly used manage these symptoms, but their safety profile in patients with AD requires further investigation.

Язык: Английский

Процитировано

1
Exploration of the Potential Association between Newer Antiseizure Medications and Arrhythmias: Integrating Pharmacovigilance and Bioinformatics Evidence DOI
Jianxing Zhou,

Zhenhui Chen,

Mengjun Zhang

и другие.

Seizure, Год журнала: 2024, Номер 123, С. 26 - 33

Опубликована: Окт. 17, 2024

Язык: Английский

Процитировано

1
Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system DOI

Haoquan Huang,

Chuwen Hu,

Fan Liu

и другие.

British Journal of Anaesthesia, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

1
The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System DOI
Jianxing Zhou, Zipeng Wei,

Weipeng Lai

и другие.

British Journal of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 10, 2024

The use of (GLP-1 RAs) among pregnant women is escalating, yet safety data remain insufficient. This study aims to comprehensively assess adverse drug reactions (ADRs) associated with GLP-1 RAs in using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Язык: Английский

Процитировано

1